Aidan Crawley, Amber Therapeutics CEO
June 9, 2024 07:01 PM EDT
Financing

UK medtech rais­es $100M for two-in-one uri­nary in­con­ti­nence treat­ment

Ayisha Sharma

News Reporter

Am­ber Ther­a­peu­tics com­plet­ed its $100 mil­lion Se­ries A raise to sup­port its im­plantable ther­a­py for mixed uri­nary in­con­ti­nence through a reg­is­tra­tional tri­al in 2026. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

A service from the Financial Times